Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?

Zacks
Zacks에서 열기
Are Medical Stocks Lagging  Halozyme Therapeutics (HALO) This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Halozyme Therapeutics (HALO) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Halozyme Therapeutics is a member of the Medical sector. This group includes 915 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Halozyme Therapeutics is currently sporting a Zacks Rank of #1 (Strong Buy).

Within the past quarter, the Zacks Consensus Estimate for HALO's full-year earnings has moved 5.4% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Our latest available data shows that HALO has returned about 52.9% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 10.4% on average. This means that Halozyme Therapeutics is performing better than its sector in terms of year-to-date returns.

One other Medical stock that has outperformed the sector so far this year is Adaptive Biotechnologies (ADPT). The stock is up 86.3% year-to-date.

In Adaptive Biotechnologies' case, the consensus EPS estimate for the current year increased 14.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

Looking more specifically, Halozyme Therapeutics belongs to the Medical - Biomedical and Genetics industry, which includes 449 individual stocks and currently sits at #92 in the Zacks Industry Rank. On average, this group has gained an average of 11.2% so far this year, meaning that HALO is performing better in terms of year-to-date returns. Adaptive Biotechnologies is also part of the same industry.

Investors interested in the Medical sector may want to keep a close eye on Halozyme Therapeutics and Adaptive Biotechnologies as they attempt to continue their solid performance.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report
 
Adaptive Biotechnologies Corporation (ADPT): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research